On Sept. 30, 2020, ViralClear Pharmaceuticals and Sorrento Therapeutics announced the companies were exploring the synergistic potential of small molecules and antibodies combination therapies against COVID-19. The agreement between ViralClear and Sorrento will allow for testing of merimepodib with neutralizing antibodies in the Golden Syrian hamster model of COVID-19.